This SLR identified only one study formally assessing treatment sequencing (RECAP), in which no significant difference in kidney outcomes was observed, based on whether SGLT2i or GLP-1 RA therapy was initiated first [17]
Zheng S, Li X, Zhang Y, Xie Q, Wong YS, Zheng W et al (2012) PEG-nanolized ultrasmall selenium nanoparticles overcome drug resistance in hepatocellular carcinoma HepG2 cells through induction of mitochondria dysfunction
Ben: Or Rybelsus, which just got FDA approval pretty recently
A clinician evaluation is necessary to determine whether such therapy warrants consideration based on individual health factors
W.WeinbergS.JosephJ.LopezM.et al
Furthermore, we did not assess body composition changes systematically over the course of GLP-1 RA treatment due to patients reluctance